Genetic aberrations in primary esophageal melanomas: Molecular analysis of c-KIT, PDGFR, KRAS, NRAS and BRAF in a series of 10 cases

Modern Pathology

Volumn 24, Issue 4, 2011, Pages 495-501

  Langer, Rupert ^a   Becker, Karen ^a   Feith, Marcus ^a   Friess, Helmut ^a   Höfler, Heinz ^a,b   Keller, Gisela ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

BRAF; c KIT; esophagus; genetics; KRAS; melanoma

Indexed keywords

B RAF KINASE; K RAS PROTEIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CHROMOSOME ABERRATION; CLINICAL ARTICLE; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MISSENSE MUTATION; MOLECULAR GENETICS; ONCOGENE C KIT; ONCOGENE N RAS; POLYMERASE CHAIN REACTION; PRIMARY ESOPHAGUS MELANOMA; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; DNA MUTATIONAL ANALYSIS; ESOPHAGEAL NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; EXONS; FEMALE; GERMANY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM STAGING; PATIENT SELECTION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-KIT; RAS PROTEINS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 79953300069     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.220     Document Type: Article

References (22)

1. Cote TR, Sobin LH. Primary melanomas of the esophagus and anorectum: epidemiologic comparison with melanoma of the skin. Melanoma Res 2009;19: 58-60.
2. Fredricks JR, Bejarano PA. Primary malignant melanoma of the esophagus with separate foci of melanoma in situ and atypical melanocytic hyperplasia in a patient positive for human immunodeficiency virus: a case report and review of the literature. Arch Pathol Lab Med 2008;132:1675-1678.
3. Sanchez AA, Wu TT, Prieto VG, et al. Comparison of primary and metastatic malignant melanoma of the esophagus: clinicopathologic review of 10 cases. Arch Pathol Lab Med 2008;132:1623-1629.
4. Sobin L, Gospodarowicz ML, Wittekind Ch. TNM Classification of Malignant Tumors. John Wiley & Sons: New York, 2010.
5. Volpin E, Sauvanet A, Couvelard A, et al. Primary malignant melanoma of the esophagus: a case report and review of the literature. Dis Esophagus 2002;15: 244-249. (Pubitemid 36007850)
6. Russo AE, Torrisi E, Bevelacqua Y, et al. Melanoma: molecular pathogenesis and emerging target therapies. Int J Oncol 2009;34:1481-1489.
7. Tuveson DA, Weber BL, Herlyn M. BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell 2003;4:95-98. (Pubitemid 37040825)
8. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353:2135-2147. (Pubitemid 41653105)
9. Willmore-Payne C, Holden JA, Tripp S, et al. Human malignant melanoma: detection of BRAFand c-kit-activating mutations by high-resolution amplicon melting analysis. Hum Pathol 2005;36: 486-493. (Pubitemid 40776001)
10. Platz A, Egyhazi S, Ringborg U, et al. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol 2008;1:395-405.
11. Terada T. Amelanotic malignant melanoma of the esophagus: report of two cases with immunohistochemical and molecular genetic study of KIT and PDGFRA. World J Gastroenterol 2009;15:2679-2683.
12. Sekine S, Nakanishi Y, Ogawa R, et al. Esophageal melanomas harbor frequent NRAS mutations unlike melanomas of other mucosal sites. Virchows Arch 2009;454:513-517.
13. Corless CL, McGreevey L, Haley A, et al. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002;160:1567-1572. (Pubitemid 34525636)
14. Loughrey MB, Waring PM, Tan A, et al. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. Fam Cancer 2007;6:301-310. (Pubitemid 47175009)
15. Torres-Cabala CA, Wang WL, Trent J, et al. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol 2009;22: 1446-1456.
16. Atsuko A, Minoru T, Hiroshi M, et al. Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. Int J Cancer 2009;124:862-868.
17. Hersey P, Bastholt L, Chiarion-Sileni V, et al. Small molecules and targeted therapies in distant metastatic disease. Ann Oncol 2009;20(Suppl 6):vi35-vi40.
18. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24:4340-4346. (Pubitemid 46630793)
19. Wong CW, Fan YS, Chan TL, et al. BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs. J Clin Pathol 2005;58:640-644. (Pubitemid 40814027)
20. Wardelmann E, Buttner R, Merkelbach-Bruse S, et al. Mutation analysis of gastrointestinal stromal tumors: increasing significance for risk assessment and effective targeted therapy. Virchows Arch 2007;451:743-749. (Pubitemid 47497944)
21. Whitwam T, VanBrocklin MW, Russo ME, et al. Differential oncogenic potential of activated RAS isoforms in melanocytes. Oncogene 2007;26:4563.
22. Hofmann UB, Kauczok-Vetter CS, Houben R, et al. Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate. Clin Cancer Res 2009;15:324-329.